Travaux scientifiques

Prof. Dr. Meral Beksaç

912 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. Subcutaneous Daratumumab With Bortezomib, Lenalidomide, and Dexamethasone: HRQoL in TE NDMM Patients from PERSEUS

    British Journal of Haematology, 2025

    Source : ORCID

  2. Treatment pathways and clinical outcomes in newly diagnosed multiple myeloma outside Europe and North America: The INTEGRATE study

    International Journal of Hematology, 2025

    DOI 10.1007/s12185-025-03972-8 PMID 40234349 1 citation (Europe PMC) Texte intégral en libre accèsSource : ORCID

  3. A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma

    Blood, 2025

    DOI 10.1182/blood.2024027873 PMID 40279508 3 citations (Europe PMC) Texte intégral en libre accèsSource : Europe PMC

  4. Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network

    HemaSphere, 2025

    DOI 10.1002/hem3.70260 PMID 41306326 20 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  5. Parameters Associated With Renal Recovery and Survival in Myeloma Patients With Acute Renal Failure to Cast Nephropathy

    American Journal of Hematology, 2025

    DOI 10.1002/ajh.70104 PMID 41134013 6 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  6. A comparison of cryopreserved and noncryopreserved peripheral blood hematopoietic stem cells for autologous transplantation in multiple myeloma: a study from the chronic malignancies working party of the EBMT

    Cytotherapy, 2025

    DOI 10.1016/j.jcyt.2025.02.008 PMID 41128705 4 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  7. MM-1045: Updated Results From the Phase 3 DREAMM-8 Study of Belantamab Mafodotin (Belamaf) Plus Pomalidomide and Dexamethasone (BPd) vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma

    Clinical Lymphoma Myeloma & Leukemia, 2025

    DOI 10.1016/s2152-2650(25)02675-8 2 citations (OpenAlex) Source : OpenAlex

  8. Minimal residual disease (MRD) negativity (neg) in patients (pts) with relapsed or refractory multiple myeloma (RRMM) treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd): Analysis from the DREAMM-8 trial.

    Journal of Clinical Oncology, 2025

    DOI 10.1200/jco.2025.43.16_suppl.7515 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  9. RETRACTED: Are Generic Imatinib Formulations Really as Effective as Originial Imatinib in Chronic Myeloid Leukemia: Real Life Data

    Research Square, 2025

    DOI 10.21203/rs.3.rs-2316364/v2 Texte intégral en libre accèsSource : OpenAlex

  10. Positron emission tomography with computed tomography (PET/CT) and minimal residual disease (MRD) for efficacy assessment in transplant-ineligible newly diagnosed myeloma (Ti NDMM) patients (pts): IMROZ analysis.

    Journal of Clinical Oncology, 2025

    DOI 10.1200/jco.2025.43.16_suppl.7551 Texte intégral en libre accèsSource : OpenAlex

  11. Belantamab mafodotin + pomalidomide + dexamethasone (BPd) vs daratumumab + bortezomib + dexamethasone (DVd) in relapsed/refractory multiple myeloma: An indirect comparison using patient-level data.

    Journal of Clinical Oncology, 2025

    DOI 10.1200/jco.2025.43.16_suppl.7536 Texte intégral en libre accèsSource : OpenAlex

  12. POSTER: MM-1039 Characterization of Infections in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin-Based Regimens From the Randomized, Phase 3 DREAMM-7 and DREAMM-8 Trials

    Clinical Lymphoma Myeloma & Leukemia, 2025

    DOI 10.1016/s2152-2650(25)01314-x Source : OpenAlex

  13. POSTER: MM-1045 Updated Results From the Phase 3 DREAMM-8 Study of Belantamab Mafodotin (Belamaf) Plus Pomalidomide and Dexamethasone (BPd) vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma

    Clinical Lymphoma Myeloma & Leukemia, 2025

    DOI 10.1016/s2152-2650(25)01318-7 Source : OpenAlex

  14. POSTER: MM-1486 Minimal Residual Disease Negativity in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide, Bortezomib, and Dexamethasone: Analysis From the DREAMM-8 Trial

    Clinical Lymphoma Myeloma & Leukemia, 2025

    DOI 10.1016/s2152-2650(25)01372-2 Source : OpenAlex

  15. MM-691: Phase 3 AQUILA Study of Daratumumab Monotherapy Versus Active Monitoring in Patients With High-Risk Smoldering Multiple Myeloma (SMM)

    Clinical Lymphoma Myeloma & Leukemia, 2025

    DOI 10.1016/s2152-2650(25)02630-8 Source : OpenAlex

  16. MM-1486: Minimal Residual Disease Negativity in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide, Bortezomib, and Dexamethasone: Analysis From the DREAMM-8 Trial

    Clinical Lymphoma Myeloma & Leukemia, 2025

    DOI 10.1016/s2152-2650(25)02743-0 Source : OpenAlex

  17. POSTER: MM-691 Phase 3 AQUILA Study of Daratumumab Monotherapy Versus Active Monitoring in Patients With High-Risk Smoldering Multiple Myeloma (SMM)

    Clinical Lymphoma Myeloma & Leukemia, 2025

    DOI 10.1016/s2152-2650(25)01280-7 Source : OpenAlex

  18. Health-Related Quality of life (HRQoL) in Frail Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Isatuximab (Isa), Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) vs VRd Alone

    Clinical Lymphoma Myeloma & Leukemia, 2025

    DOI 10.1016/s2152-2650(25)03842-x Source : OpenAlex

  19. Somatic variants and frequencies of familial myeloma germline predisposition genes among patients within the CoMMpass dataset

    Expert Review of Hematology, 2025

    DOI 10.1080/17474086.2025.2567299 PMID 40996854 Source : OpenAlex

  20. A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant

    Future Oncology, 2025

    DOI 10.1080/14796694.2025.2560134 PMID 41058194 Texte intégral en libre accèsSource : OpenAlex

  21. Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis

    Blood, 2025

    DOI 10.1182/blood-2025-5820 Texte intégral en libre accèsSource : OpenAlex

  22. Indirect treatment comparison of belantamab mafodotin + pomalidomide + dexamethasone versus comparator regimens in lenalidomide-exposed relapsed/refractory multiple myeloma: A network meta-analysis

    Blood, 2025

    DOI 10.1182/blood-2025-7567 Source : OpenAlex

  23. Long-term outcomes of syngeneic transplantation in multiple myeloma: Valuable legacy or obsolete option? a study from the chronic malignancies working party of the EBMT

    Blood, 2025

    DOI 10.1182/blood-2025-6357 Texte intégral en libre accèsSource : OpenAlex

  24. Outcomes of multiple myeloma (MM) patients with del 17p as a sole high risk cytogenetic abnormality who underwent either single or tandem upfront autologous stem cell transplant approaches in EBMT centres between 2016 and 2022

    Blood, 2025

    DOI 10.1182/blood-2025-4583 Source : OpenAlex

  25. Subcutaneous Daratumumab (Dara) plus Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients With Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival (OS) and Final Major Organ Deterioration Progression-Free Survival Results From the Phase 3 Andromeda

    UCL Discovery (University College London), 2025

    Source : OpenAlex

  26. RESISTANCE MECHANISMS IN MULTIPLE MYELOMA IMMUNOTHERAPY

    Turkiye Klinikleri eBooks, 2025

    DOI 10.5336/978-625-395-657-8_p59 Source : OpenAlex

  27. In vivo and in vitro effects of cord blood hematopoietic stem and progenitor cell (HSPC) expansion using valproic acid and/or nicotinamide

    Current Research in Translational Medicine, 2024

    DOI 10.1016/j.retram.2024.103444 PMID 38447268 1 citation (Europe PMC) Source : OpenAlex

  28. Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies

    Blood Cancer Journal, 2024

    DOI 10.1038/s41408-024-01149-w PMID 39609425 5 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  29. A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma

    Blood Advances, 2024

    DOI 10.1182/bloodadvances.2024013101 PMID 39024542 13 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  30. Lenfoplazmasitik Lenfomada Yeni Nesil Dizileme Yöntemiyle Mutasyon İncelemesinin Tanı ve Tedavi Planında Yeri

    LLM Dergi, 2024

    DOI 10.5578/llm.202401127 Texte intégral en libre accèsSource : ORCID

  31. A Deeper Look Into Infections Among Myeloma Patients Treated With Daratumumab or Belantamab Mafodotin

    Clinical Lymphoma Myeloma and Leukemia, 2024

    Source : ORCID

  32. A Germline Variant of BNIP1 Gene (rs28199) is Associated with Familial Multiple Myeloma

    Clinical Lymphoma Myeloma and Leukemia, 2024

    Source : ORCID

  33. A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma

    Future Oncology, 2024

    DOI 10.1080/14796694.2024.2394323 PMID 39287147 2 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  34. Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide

    Blood, 2024

    DOI 10.1182/blood-2024-199282 6 citations (OpenAlex) Source : ORCID

  35. Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma

    New England Journal of Medicine, 2024

    DOI 10.1056/nejmoa2403407 PMID 38828951 157 citations (Europe PMC) Source : ORCID

  36. Belantamab Mafodotin, Pomalidomide, and Dexamethasone vs Pomalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Patient-Reported Outcomes from DREAMM-8

    Clinical Lymphoma Myeloma and Leukemia, 2024

    Source : ORCID

  37. Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison

    Leukemia and Lymphoma, 2024

    DOI 10.1080/10428194.2023.2300051 PMID 38345269 5 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  38. Characterization and Management of Ocular Events in Patients Treated With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone in the DREAMM-8 Study

    Clinical Lymphoma Myeloma and Leukemia, 2024

    Source : ORCID

  39. Current Landscape of iPSC Haplobanks

    Stem Cell Reviews and Reports, 2024

    DOI 10.1007/s12015-024-10783-7 PMID 39276260 13 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  40. Current barriers and recommendations on the diagnosis of transthyretin amyloid cardiomyopathy: a Delphi study

    Frontiers in Cardiovascular Medicine, 2024

    DOI 10.3389/fcvm.2024.1299261 PMID 38333414 3 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  41. Daratumumab (DARA) plus bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial

    Journal of Clinical Oncology, 2024

    Source : ORCID

  42. Daratumumab (DARA)/Bortezomib/Lenalidomide/Dexamethasone (D-VRd) With D-R Maintenance (Maint) in Transplant-eligible (TE) Newly Diagnosed Myeloma (NDMM): PERSEUS Cytogenetic Risk Analysis

    Clinical Lymphoma Myeloma and Leukemia, 2024

    Source : ORCID

  43. Daratumumab maintenance in patients with myeloma

    The Lancet Oncology, 2024

    DOI 10.1016/s1470-2045(24)00341-3 PMID 38889736 1 citation (Europe PMC) Source : ORCID

  44. Daratumumab plus Bortezomib/ Lenalidomide/Dexamethasone (D-VRd) in Transplant-Eligible (TE) Patients With Newly Diagnosed Myeloma (NDMM): Analysis of the Phase 3 PERSEUS Study Based on High-Risk Cytogenetic Abnormalities (HRCAs)

    Clinical Lymphoma Myeloma and Leukemia, 2024

    Source : ORCID

  45. Daratumumab plus Bortezomib/ Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study

    Clinical Lymphoma Myeloma and Leukemia, 2024

    Source : ORCID

  46. Daratumumab plus Bortezomib/Lenalidomide/ Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study

    Clinical Lymphoma Myeloma and Leukemia, 2024

    Source : ORCID

  47. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

    New England Journal of Medicine, 2024

    DOI 10.1056/nejmoa2312054 PMID 38084760 482 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  48. Efficacy of venetoclax-dexamethasone (VenDex) v pomalidomide-dexamethasone (PomDex) in patients (Pts) with t(11;14)-positive relapsed/refractory multiple myeloma [t(11;14)+ RRMM]: Phase 3 CANOVA study biomarker subgroup analysis

    Journal of Clinical Oncology, 2024

    Source : ORCID

  49. In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT

    Bone Marrow Transplantation, 2024

    DOI 10.1038/s41409-023-02160-8 PMID 38297040 1 citation (Europe PMC) Texte intégral en libre accèsSource : ORCID

  50. Inhibition of O6-methylguanine-DNA-methyltransferase (MGMT) by lomeguatrib reduces multiple myeloma cell viability and impairs DNA repair in MGMT-proficient cells

    Chemical Biology and Drug Design, 2024

    DOI 10.1111/cbdd.14465 1 citation (OpenAlex) Texte intégral en libre accèsSource : ORCID